FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293089945> ?p ?o ?g. }

• W4293089945 abstract "Background: The molecular mechanisms of EWS-FLI-mediating target genes and downstream pathways may provide a new way in the targeted therapy of Ewing sarcoma. Meanwhile, enhancers transcript non-coding RNAs, known as enhancer RNAs (eRNAs), which may serve as potential diagnosis markers and therapeutic targets in Ewing sarcoma. Materials and methods: Differentially expressed genes (DEGs) were identified between 85 Ewing sarcoma samples downloaded from the Treehouse database and 3 normal bone samples downloaded from the Sequence Read Archive database. Included in DEGs, differentially expressed eRNAs (DEeRNAs) and target genes corresponding to DEeRNAs (DETGs), as well as the differentially expressed TFs, were annotated. Then, cell type identification by estimating relative subsets of known RNA transcripts (CIBERSORT) was used to infer portions of infiltrating immune cells in Ewing sarcoma and normal bone samples. To evaluate the prognostic value of DEeRNAs and immune function, cross validation, independent prognosis analysis, and Kaplan-Meier survival analysis were implemented using sarcoma samples from the Cancer Genome Atlas database. Next, hallmarks of cancer by gene set variation analysis (GSVA) and immune gene sets by single-sample gene set enrichment analysis (ssGSEA) were identified to be significantly associated with Ewing sarcoma. After screening by co-expression analysis, most significant DEeRNAs, DETGs and DETFs, immune cells, immune gene sets, and hallmarks of cancer were merged to construct a co-expression regulatory network to eventually identify the key DEeRNAs in tumorigenesis of Ewing sarcoma. Moreover, Connectivity Map Analysis was utilized to identify small molecules targeting Ewing sarcoma. External validation based on multidimensional online databases and scRNA-seq analysis were used to verify our key findings. Results: A six-different-dimension regulatory network was constructed based on 17 DEeRNAs, 29 DETFs, 9 DETGs, 5 immune cells, 24 immune gene sets, and 8 hallmarks of cancer. Four key DEeRNAs (CCR1, CD3D, PHLDA1, and RASD1) showed significant co-expression relationships in the network. Connectivity Map Analysis screened two candidate compounds, MS-275 and pyrvinium, that might target Ewing sarcoma. PHLDA1 (key DEeRNA) was extensively expressed in cancer stem cells of Ewing sarcoma, which might play a critical role in the tumorigenesis of Ewing sarcoma. Conclusion: PHLDA1 is a key regulator in the tumorigenesis and progression of Ewing sarcoma. PHLDA1 is directly repressed by EWS/FLI1 protein and low expression of FOSL2, resulting in the deregulation of FOX proteins and CC chemokine receptors. The decrease of infiltrating T-lymphocytes and TNFA signaling may promote tumorigenesis and progression of Ewing sarcoma." @default.
• W4293089945 created "2022-08-26" @default.
• W4293089945 creator A5004419821 @default.
• W4293089945 creator A5012697750 @default.
• W4293089945 creator A5018061406 @default.
• W4293089945 creator A5026695288 @default.
• W4293089945 creator A5035801000 @default.
• W4293089945 creator A5040873593 @default.
• W4293089945 creator A5046040180 @default.
• W4293089945 creator A5049341927 @default.
• W4293089945 creator A5053538334 @default.
• W4293089945 creator A5053608292 @default.
• W4293089945 creator A5068923431 @default.
• W4293089945 creator A5076699095 @default.
• W4293089945 creator A5077764391 @default.
• W4293089945 creator A5080334927 @default.
• W4293089945 creator A5083958579 @default.
• W4293089945 date "2022-08-25" @default.
• W4293089945 modified "2023-09-25" @default.
• W4293089945 title "Repression of enhancer RNA PHLDA1 promotes tumorigenesis and progression of Ewing sarcoma via decreasing infiltrating T‐lymphocytes: A bioinformatic analysis" @default.
• W4293089945 cites W1566720599 @default.
• W4293089945 cites W1803045814 @default.
• W4293089945 cites W1888783223 @default.
• W4293089945 cites W18929574 @default.
• W4293089945 cites W1963644478 @default.
• W4293089945 cites W1968401667 @default.
• W4293089945 cites W1969037652 @default.
• W4293089945 cites W1969415039 @default.
• W4293089945 cites W1969770714 @default.
• W4293089945 cites W1971516612 @default.
• W4293089945 cites W1971884763 @default.
• W4293089945 cites W1977918192 @default.
• W4293089945 cites W1980587308 @default.
• W4293089945 cites W1980631483 @default.
• W4293089945 cites W1994219871 @default.
• W4293089945 cites W2008679675 @default.
• W4293089945 cites W2012034410 @default.
• W4293089945 cites W2014787267 @default.
• W4293089945 cites W2015845481 @default.
• W4293089945 cites W2024873768 @default.
• W4293089945 cites W2025989401 @default.
• W4293089945 cites W2030689322 @default.
• W4293089945 cites W2051305915 @default.
• W4293089945 cites W2063602321 @default.
• W4293089945 cites W2066280610 @default.
• W4293089945 cites W2067051871 @default.
• W4293089945 cites W2068868975 @default.
• W4293089945 cites W2069351898 @default.
• W4293089945 cites W2071520231 @default.
• W4293089945 cites W2081098333 @default.
• W4293089945 cites W2094468530 @default.
• W4293089945 cites W2101375091 @default.
• W4293089945 cites W2121604817 @default.
• W4293089945 cites W2123879591 @default.
• W4293089945 cites W2124526610 @default.
• W4293089945 cites W2127438438 @default.
• W4293089945 cites W2142433690 @default.
• W4293089945 cites W2148504057 @default.
• W4293089945 cites W2149441684 @default.
• W4293089945 cites W2157357478 @default.
• W4293089945 cites W2159707944 @default.
• W4293089945 cites W2164559547 @default.
• W4293089945 cites W2170830174 @default.
• W4293089945 cites W2214074259 @default.
• W4293089945 cites W2266703738 @default.
• W4293089945 cites W2320280739 @default.
• W4293089945 cites W2406160780 @default.
• W4293089945 cites W2417925437 @default.
• W4293089945 cites W2607129810 @default.
• W4293089945 cites W2793584816 @default.
• W4293089945 cites W2795867722 @default.
• W4293089945 cites W2797069917 @default.
• W4293089945 cites W2806256591 @default.
• W4293089945 cites W2886988891 @default.
• W4293089945 cites W2889689714 @default.
• W4293089945 cites W2898215009 @default.
• W4293089945 cites W2901027836 @default.
• W4293089945 cites W2908139053 @default.
• W4293089945 cites W2918297277 @default.
• W4293089945 cites W2944727022 @default.
• W4293089945 cites W2979624544 @default.
• W4293089945 cites W3001562725 @default.
• W4293089945 cites W3011087857 @default.
• W4293089945 cites W3015261626 @default.
• W4293089945 cites W3165484362 @default.
• W4293089945 cites W4211227438 @default.
• W4293089945 doi "https://doi.org/10.3389/fgene.2022.952162" @default.
• W4293089945 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36092920" @default.
• W4293089945 hasPublicationYear "2022" @default.
• W4293089945 type Work @default.
• W4293089945 citedByCount "0" @default.
• W4293089945 crossrefType "journal-article" @default.
• W4293089945 hasAuthorship W4293089945A5004419821 @default.
• W4293089945 hasAuthorship W4293089945A5012697750 @default.
• W4293089945 hasAuthorship W4293089945A5018061406 @default.
• W4293089945 hasAuthorship W4293089945A5026695288 @default.
• W4293089945 hasAuthorship W4293089945A5035801000 @default.
• W4293089945 hasAuthorship W4293089945A5040873593 @default.
• W4293089945 hasAuthorship W4293089945A5046040180 @default.
• W4293089945 hasAuthorship W4293089945A5049341927 @default.

• next